

Research Article

Open Access

Palm-Derived Tocotrienols as Precision Adjuncts in Type 2 Diabetes: Residual Oxidative, Inflammatory, and Cardiorenal Risk in the SGLT2–GLP-1 Era A Critical Review

Loso Judijanto

IPOSS Jakarta, Indonesia

ABSTRACT

Type 2 diabetes mellitus (T2DM) management has shifted from glucose-centered treatment toward integrated cardiovascular, kidney, and metabolic risk reduction through sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), renin–angiotensin system blockade, lipid-lowering therapy, and, in selected patients, finerenone. Nevertheless, substantial residual biological risk persists through oxidative stress, metabolic inflammation, endothelial dysfunction, mitochondrial injury, and microvascular damage. Palm-derived tocotrienols possess antioxidant, anti-inflammatory, and metabolic activities that intersect several of these pathways. This critical qualitative literature review evaluates whether tocotrienols retain a plausible adjunctive role within contemporary T2DM therapy. Evidence published during 2020–2026 was interpreted across four domains: residual T2DM pathobiology, mechanisms of current organ-protective drugs, tocotrienol pharmacology and bioavailability, and human metabolic and organ-specific outcomes. Tocotrienol trials demonstrate signals involving HbA1c, insulin resistance, inflammatory and oxidative biomarkers, renal function, nerve conduction and hepatic-metabolic outcomes, but effects are heterogeneous and generally derive from relatively small trials. Crucially, convincing evidence that tocotrienols improve hard cardiovascular or kidney outcomes or provide incremental benefit when added to contemporary SGLT2/GLP-1/finerenone-based therapy is absent. Future research should therefore move beyond generic antioxidant supplementation toward standardised formulations, pharmacokinetic confirmation, biomarker-enriched populations and adequately powered add-on trials. Palm tocotrienols are best considered a promising precision-adjunct hypothesis rather than an established component of contemporary diabetes therapy.

***Corresponding author**

Loso Judijanto, IPOSS Jakarta, Indonesia.

Received: August 03, 2026; **Accepted:** September 08, 2026; **Published:** September 19, 2026

Keywords: Palm Tocotrienols, Tocotrienol-Rich Fraction, Type 2 Diabetes Mellitus, SglT2 Inhibitors, Glp-1 Receptor Agonists, Oxidative Stress, Inflammation, Nlrp3 Inflammasome, Diabetic Kidney Disease, Residual Cardiorenal Risk

JEL Classification: I10-Health General, I12-Health Behavior, I15-Health and Economic Development, I18-Government Policy, Regulation and Public Health, Q16-R&D, Agricultural Technology and Bio-based Innovation

Introduction

Type 2 diabetes mellitus remains one of the defining chronic diseases of the twenty-first century. The Global Burden of Disease 2021 analysis estimated that approximately 529 million people were living with diabetes in 2021 and projected that the global burden could exceed 1.3 billion by 2050, with T2DM accounting for the overwhelming majority of cases. The significance of this expansion is not confined to hyperglycaemia diabetes accelerates atherosclerotic cardiovascular disease, heart failure, Chronic Kidney Disease (CKD), neuropathy, retinopathy, peripheral vascular disease and multiple forms of metabolic-organ dysfunction that collectively determine disability, mortality and health-system burden [1].

The therapeutic paradigm for T2DM has changed correspondingly. Contemporary care no longer regards glucose reduction as an adequate surrogate for comprehensive risk modification. The 2026 American Diabetes Association (ADA) Standards of Care explicitly integrate glycaemic management with obesity treatment, cardiovascular protection and kidney protection. In appropriate patients, SGLT2 inhibitors and GLP-1–based therapies are selected partly because of cardiovascular and renal benefits that extend beyond their effects on HbA1c, while nonsteroidal mineralocorticoid receptor antagonism with finerenone provides another layer of protection in albuminuric diabetic CKD [2–5].

This transformation is supported by unusually strong clinical evidence. Dapagliflozin reduced kidney and cardiovascular events in CKD in DAPA-CKD, empagliflozin reduced progression of kidney disease or cardiovascular death in EMPA-KIDNEY, and longer-term EMPA-KIDNEY follow-up suggested persistence of benefit after the active trial period [6–8]. Finerenone reduced kidney outcomes in FIDELIO-DKD and cardiovascular events in FIGARO-DKD, with FIDELITY confirming benefits across a broad CKD spectrum [9–11]. More recently, semaglutide reduced clinically important kidney outcomes in FLOW, while cardiovascular outcome evidence from SELECT and newer incretin trials has broadened the concept of cardiometabolic

protection [12-14]. These advances raise a difficult question for nutraceutical and bioactive compound research. A candidate intervention should no longer be judged against untreated diabetes, outdated background therapy or glucose reduction alone. Instead, its value should be assessed against a therapeutic baseline in which multiple pharmacological classes already reduce cardiorenal events and influence inflammation, oxidative stress, adiposity, endothelial function and renal haemodynamics. Meta-analytic evidence shows class-wide cardiovascular and kidney protection with SGLT2 inhibitors, while contemporary GLP-1 RA meta-analysis demonstrates clinically relevant kidney and cardiovascular benefits [15-16]. Recent syntheses of diabetic kidney disease further emphasize that SGLT2 inhibitors and GLP-1 RAs provide partly complementary renal protection through haemodynamic, metabolic and anti-inflammatory mechanisms rather than through glycaemic effects alone [17].

Palm-derived tocotrienols provide a useful test case. Tocotrienols belong to the vitamin E family but differ structurally and biologically from tocopherols through an unsaturated isoprenoid side chain that influences membrane distribution and cellular activity. Palm oil is an important natural source of α -, γ - and δ -tocotrienols, generally administered experimentally as a tocotrienol-rich fraction (TRF) or as selected purified isomers. Contemporary reviews describe antioxidant, anti-inflammatory, metabolic, vascular and other biological effects that cannot be reduced to conventional α -tocopherol physiology [18-19].

Clinical interest has been sustained by small trials showing favourable effects on glycaemic control, oxidative and inflammatory biomarkers, diabetic kidney function, nerve conduction and metabolic liver disease. However, the evidence is not uniform. A T2DM-specific meta-analysis reported a modest pooled reduction in HbA1c after TRF supplementation, especially in shorter-duration studies and patients with shorter diabetes duration, while blood pressure and hs-CRP did not improve significantly [20]. A broader meta-analysis found no consistent effect on many anthropometric, inflammatory, glycaemic and hepatic biomarkers [21]. Similarly, a meta-analysis focused on inflammation and oxidative stress found that the pooled CRP effect was heavily influenced by one δ -tocotrienol study and that IL-6, TNF- α and malondialdehyde were not consistently reduced [22]. A recent systematic review of 30 randomised controlled trials of palm-derived TRF likewise concluded that the overall clinical signal is promising but remains constrained by heterogeneity in dose, formulation, treatment duration and outcome selection [23]. The question for 2026 is therefore no longer whether tocotrienols possess antioxidant properties. It is whether these properties translate into incremental clinical benefit within a treatment environment already populated by drugs with proven cardiorenal effects and partly overlapping anti-inflammatory and redox actions. This review critically evaluates that question. It focuses on residual biological risk, mechanistic complementarity and redundancy, contemporary human evidence, translational inconsistencies, pharmacokinetic limitations and the design requirements for future add-on trials. Palm tocotrienols are evaluated neither as substitutes for guideline-directed therapy nor as inherently beneficial because of their natural origin, but as a testable precision-adjunct hypothesis.

Literature Review: Conceptual and Theoretical Foundations Tocotrienols within the Vitamin E Family

Vitamin E comprises four tocopherols and four tocotrienols designated α , β , γ and δ according to methyl substitution on the

chromanol ring. Tocopherols possess a saturated phytyl side chain, whereas tocotrienols possess an unsaturated farnesyl-like chain containing three double bonds. This structural distinction changes membrane mobility, distribution and interactions with biological targets. Tocotrienols occur in palm oil, rice bran and selected cereals and seeds, but palm-derived preparations have particular translational relevance because they can provide mixed α -, γ - and δ -tocotrienols together with varying quantities of tocopherol [18].

The term “vitamin E” can consequently obscure substantial pharmacological heterogeneity. α -Tocopherol has high affinity for α -tocopherol transfer protein and predominates in circulating and tissue vitamin-E pools, whereas tocotrienol disposition differs by isoform, dose, formulation and feeding conditions. Tocotrienols are therefore not simply “stronger vitamin E.” Their therapeutic interpretation requires specification of the chemical species administered, the relative proportions of tocotrienol isomers, accompanying α -tocopherol, formulation technology and achieved systemic exposure [19,24].

Pharmacokinetics represent an important translational limitation. Human studies synthesized by Sharif et al [24]. indicate meaningful differences in exposure among annatto-derived δ -tocotrienol and mixed palm-derived preparations. Oral absorption is affected by the lipid matrix, dose and formulation. Pharmaceutical approaches including self-emulsifying drug-delivery systems have therefore been investigated to increase dispersion, intestinal absorption and reproducibility of systemic exposure [25]. Consequently, apparently contradictory clinical trials may partly represent comparisons among different products rather than repeated tests of a single pharmacological intervention.

Residual Pathobiology in T2DM

T2DM arises through complex interactions among insulin resistance, progressive β -cell dysfunction, adipose-tissue dysregulation, ectopic lipid accumulation, altered substrate metabolism and chronic hyperglycaemia. Oxidative stress is both a consequence and amplifier of these processes. Excess reactive oxygen species can arise through mitochondrial electron transport, NADPH oxidases, endoplasmic-reticulum stress and other pathways, while impaired endogenous antioxidant responses weaken cellular resilience [26-27].

Oxidative stress is intertwined with inflammation rather than operating as an independent pathway. Metabolic danger signals, lipotoxicity, hyperglycaemia and mitochondrial disturbance can activate inflammatory networks including NF- κ B and the NLRP3 inflammasome. NLRP3 integrates a range of metabolic signals and promotes maturation of interleukin-1 β and interleukin-18, thereby contributing to insulin resistance, β -cell stress, vascular inflammation and organ injury [28-29]. The resulting low-grade “meta-inflammatory” state provides an important conceptual basis for therapies that improve outcomes without relying exclusively on additional glucose lowering. Advanced glycation end products provide another mechanism linking metabolic exposure with chronic vascular damage. AGE formation and AGE–RAGE signalling promote oxidative stress, endothelial activation, inflammation and tissue remodelling. These processes are relevant to microvascular and macrovascular complications and may persist despite short-term normalisation of circulating glucose [30] Endothelial dysfunction likewise reflects combined oxidative, inflammatory, metabolic and nitric-oxide abnormalities. Contemporary reviews emphasize that nonspecific antioxidant supplementation has often failed to translate into cardiovascular

outcome benefits, highlighting the distinction between correcting an oxidative biomarker and changing disease trajectory [31]. A recent state-of-the-art review of diabetic kidney disease further highlights the convergence of glomerular hyperfiltration, podocyte injury, tubulointerstitial inflammation and fibrosis, reinforcing the need to distinguish persistent pathobiology from pathways already targeted by contemporary therapies [32].

Modern Therapies Already Modify Many “Residual” Pathways
SGLT2 inhibitors were initially developed as glucose-lowering drugs through inhibition of proximal tubular glucose reabsorption. Their clinical effects, however, extend far beyond glycosuria. Restoration of tubuloglomerular feedback, reduction in intraglomerular pressure, natriuresis, altered substrate utilization, reduced tubular workload, improved kidney oxygenation and effects on inflammation and oxidative stress are among the proposed mechanisms of cardiorenal protection [33–35].

This matters directly for tocotrienol research. SGLT2 inhibitors have themselves been associated with reductions in inflammatory and oxidative-stress pathways. A systematic review of biomarker studies found evidence that SGLT2 inhibition can influence inflammatory and redox markers, although effects were not uniform across studies and analytes [36]. Kidney-focused mechanistic literature likewise identifies oxidative stress, inflammatory signalling and renal fibrosis among potential downstream targets of SGLT2 inhibition [37–38]. More recent work has characterised systemic and organ-specific anti-inflammatory actions as a potentially important component of this drug class [39]. Contemporary clinical reviews similarly emphasize that the kidney benefits of SGLT2 inhibitors coexist with, rather than

replace, the complementary metabolic and vascular actions of GLP-1 receptor agonists [17].

GLP-1 RAs create similar conceptual overlap. Their established actions include glucose-dependent insulinotropic effects, reduction of appetite and body weight, and improved metabolic control, but mechanistic literature also supports effects on inflammation, vascular biology, lipid metabolism and cardiometabolic signalling [40]. Clinical analyses demonstrate substantial decreases in CRP during semaglutide-induced weight loss, while broader reviews describe anti-inflammatory actions across relevant tissues [41–42]. Meta-inflammation may therefore be modified directly and indirectly by both major modern drug classes [43].

This creates the central theoretical problem of the present review. A nutraceutical that reduces oxidative stress or inflammatory signalling in isolation may have little additional effect when the same pathway has already been modified by weight loss, improved glycaemia, altered renal energetics and organ-protective pharmacotherapy. Conversely, incomplete pathway normalisation could leave room for complementary activity. The therapeutic niche for tocotrienols therefore depends not only on whether they possess biological activity but on whether their activity remains quantitatively important after modern therapy.

Figure 1 positions palm tocotrienols within this changed therapeutic hierarchy. Rather than placing tocotrienols beside SGLT2 inhibitors or GLP-1 RAs as competing antidiabetic therapies, the model locates them downstream of an established guideline-directed treatment baseline and asks whether they can address residual oxidative, inflammatory, endothelial or microvascular biology.




Figure 1: Contemporary Therapeutic Baseline and the Proposed Tocotrienol Niche

Figure 1 shows that the model emphasizes a necessary hierarchy of evidence. Contemporary drugs first establish clinically meaningful glycaemic, weight, cardiovascular and renal protection. Residual biological pathways may then remain incompletely normalized. Tocotrienols are hypothesized to influence several of these pathways, but the relevant research question is whether that influence produces additional benefit after the modern therapeutic baseline is already present. This distinction prevents mechanistic plausibility from being confused with comparative or additive effectiveness.

Methods

This article employed a critical qualitative literature review methodology rather than a systematic literature review or meta-analysis. The purpose was interpretive synthesis: to integrate contemporary mechanistic evidence, human intervention studies, major cardiorenal outcome trials and pharmacological concepts in order to evaluate the potential adjunctive position of palm-derived tocotrienols in modern T2DM therapy.

Literature identification focused primarily on publications from January 2020 through September 2026. PubMed-indexed records and major journal and publisher databases were examined using combinations of terms related to tocotrienol, palm tocotrienol, tocotrienol-rich fraction, type 2 diabetes, insulin resistance, oxidative stress, inflammation, NLRP3, diabetic kidney disease, neuropathy, SGLT2 inhibitor, GLP-1 receptor agonist, semaglutide, finerenone, cardiorenal outcomes and bioavailability. Citation chaining from relevant contemporary reviews and clinical trials was used to identify additional studies.

Selection was purposive rather than exhaustive. Priority was assigned to peer-reviewed human randomised trials, meta-analyses useful for interpreting the consistency of clinical signals, major randomised outcome trials defining the current standard-of-care context, recent mechanistic reviews in reputable journals, and experimental studies where they addressed a translational question not adequately resolved in humans. Older studies were deliberately excluded from the principal reference corpus to maintain emphasis on literature published since 2020.

Evidence was organized into thematic domains covering the contemporary therapeutic baseline; residual oxidative and inflammatory biology; tocotrienol pharmacology and pharmacokinetics; glycaemic and insulin-resistance outcomes; oxidative and inflammatory biomarkers; kidney, neurological and hepatic-metabolic outcomes; formulation and exposure; and the gap between biological plausibility and incremental clinical efficacy. This thematic organisation was used to compare mechanistic convergence with clinical outcome evidence and to identify where the evidence base remains weakest.

Interpretation used an evidence hierarchy. Large randomised cardiovascular or kidney outcome trials were considered stronger for clinical efficacy than biomarker trials; human randomised tocotrienol studies were considered stronger than animal and cell studies; and mechanistic evidence was used to explain biological plausibility rather than to infer clinical benefit. Discordance between mechanistic and clinical results was treated as a finding rather than selectively resolved in favour of positive studies.

This methodology intentionally differs from a systematic review. It does not claim exhaustive retrieval of every eligible article, does not employ PRISMA flow enumeration, does not calculate pooled effect sizes and does not present a formal study-level risk-of-bias score. Its strength lies instead in theoretically guided triangulation across therapeutic context, mechanism, pharmacology and clinical outcomes. Accordingly, conclusions are framed as critical interpretations and research hypotheses rather than quantitative estimates of treatment effect.

Results: Thematic Findings

Theme 1: The Therapeutic Baseline Has Been Reset by Organ-Protective Therapy

The most important contextual finding is that any future tocotrienol

intervention is entering a treatment landscape fundamentally different from that of early vitamin-E supplementation studies. DAPA-CKD demonstrated substantial kidney protection with dapagliflozin in CKD populations with and without diabetes [6]. EMPA-KIDNEY extended evidence for empagliflozin across a broad CKD population, and post-trial follow-up demonstrated persistence of favourable cardiorenal effects beyond the original randomised treatment period [7-8]. A meta-analysis of major SGLT2 outcome trials also showed consistent reductions in heart-failure hospitalisation and kidney outcomes across the drug class [15].

Mineralocorticoid-receptor antagonism has added another evidence-based mechanism. FIDELIO-DKD showed that finerenone reduced kidney-disease progression in patients with T2DM and CKD, while FIGARO-DKD showed cardiovascular benefit in a broader spectrum of diabetic kidney disease [9-10]. The prespecified FIDELITY pooled analysis strengthened estimates of both cardiovascular and kidney protection across more than 13,000 participants [11]. Recent consensus-oriented literature similarly positions finerenone as an add-on to optimised RAS blockade and SGLT2 inhibition rather than as a stand-alone replacement for these foundational therapies [44].

The GLP-1 field has advanced similarly. FLOW demonstrated that semaglutide reduced clinically important kidney outcomes and cardiovascular death in T2DM with CKD.13 SELECT demonstrated reduction in major cardiovascular events with semaglutide in people with established cardiovascular disease and overweight or obesity even without diabetes, illustrating the broader cardiometabolic consequences of incretin-based therapy [12]. A contemporary meta-analysis confirms kidney and cardiovascular protection across GLP-1 RA trials, while newer tirzepatide outcome evidence further illustrates the rapid evolution toward integrated weight, glycaemic and cardiovascular intervention [14,16].

Therefore, improvements in HbA1c or CRP cannot alone establish the contemporary clinical value of tocotrienols. An adjunct must either generate additional improvement in an important residual pathway, produce clinically meaningful benefit not achieved by existing therapy, improve tolerability or adherence, or benefit a definable subgroup for whom residual risk remains particularly high.

Theme 2: Residual Biological Risk Nevertheless Remains Plausible

The success of modern drugs does not imply complete normalisation of diabetic biology. Chronic hyperglycaemia, insulin resistance, excess adiposity, lipid abnormalities, mitochondrial dysfunction, oxidative stress, inflammatory activation and AGE accumulation can coexist for years before organ-protective treatment is initiated. Structural vascular and renal changes may subsequently become partially self-sustaining [26,27,30].

Inflammatory pathways are especially relevant. NLRP3 inflammasome activation integrates metabolic, mitochondrial and danger signals and can contribute to β -cell impairment, insulin resistance, vascular inflammation and kidney injury [28-29]. In diabetic kidney disease, inflammatory-cell activation and cytokine signalling accompany haemodynamic and metabolic disturbances and may contribute to progressive fibrosis [38].

However, residual biology should not automatically be equated with residual therapeutic opportunity. SGLT2 inhibitors already influence renal oxygen demand, inflammatory activation, oxidative pathways and metabolic substrate handling, while GLP-1 RAs produce weight loss and have anti-inflammatory effects that can reduce upstream drivers of oxidative and endothelial stress [37,39,40]. The relevant target for tocotrienols is therefore the fraction of these abnormalities that remains pharmacologically modifiable after optimised treatment.

Theme 3: Tocotrienols Possess Credible Multitarget Biological Activity

Contemporary biochemical and translational literature supports multiple biological effects of tocotrienols. Their chromanol ring provides radical-scavenging capability, while their unsaturated side chain changes distribution within lipid environments and cellular membranes. Beyond direct antioxidant activity, tocotrienols have been associated with modulation of inflammatory signalling, lipid metabolism, cell-survival pathways and metabolic regulation [18-19].

Experimental evidence also supports effects on diabetes-associated organ dysfunction [45]. studying a modified dehydro-tocotrienol- β compound in db/db mice, reported improvements across oxidative-stress-associated diabetic complications, including metabolic and organ-function outcomes. Such evidence demonstrates pharmacological plausibility but should not be interpreted as proof for palm TRF because a modified experimental compound is not pharmacokinetically equivalent to a human palm-derived preparation.

Human evidence provides a stronger but more variable signal [46]. randomised 110 patients with T2DM receiving oral glucose-lowering therapy to δ -tocotrienol or placebo for 24 weeks. δ -Tocotrienol improved fasting glucose, insulin, HOMA-IR and HbA1c and decreased MDA, hs-CRP, TNF- α and IL-6 while altering selected miRNAs. These results support simultaneous metabolic, oxidative and inflammatory activity, but they derive from one relatively small study and a treatment environment that does not necessarily represent contemporary multidrug cardiorenal therapy.

Theme 4: Glycaemic Effects Appear Real but Modest and Heterogeneous

The strongest aggregate T2DM-specific synthesis comes from [30]. Across ten randomised controlled studies, TRF supplementation at doses approximately 250–400 mg/day produced a statistically significant but modest reduction in HbA1c of approximately 0.23 percentage points. Effects appeared larger in interventions shorter than six months and among participants with diabetes duration below ten years. Blood pressure and hs-CRP did not significantly improve.

The finding is clinically intriguing because it suggests phenotype or disease-stage dependence. Earlier T2DM may preserve sufficient β -cell function and metabolic flexibility for antioxidant or anti-inflammatory modulation to produce detectable glycaemic effects. In longstanding disease, progressive β -cell failure, vascular injury, polypharmacy and advanced complications could reduce responsiveness. This interpretation remains hypothetical because the subgroup evidence is based on relatively small numbers.

Prediabetes data also suggest a potential early-disease signal [47]. reported improvements in fasting glucose, HbA1c, insulin and HOMA-IR after δ -tocotrienol supplementation in individuals with prediabetes. The study supports the possibility that tocotrienols influence early insulin-resistance physiology, although the short duration and modest sample size limit inference concerning progression to diabetes.

Evidence from metabolically related conditions is supportive but indirect [48]. reported improvements in insulin resistance, inflammatory markers, oxidative stress and hepatic steatosis with δ -tocotrienol in nonalcoholic fatty liver disease. In a subsequent active-controlled trial, δ -tocotrienol and α -tocopherol both improved insulin resistance and hepatic-steatosis measures, while δ -tocotrienol produced greater changes in selected inflammatory, adipokine and body-weight measures [49]. These findings support systemic metabolic actions but cannot be directly transferred to a modern T2DM population receiving SGLT2 or GLP-1 therapy.

Theme 5: Anti-inflammatory and Antioxidant Effects are Less Consistent than Individual Studies Suggest

One of the most important findings of this review is the difference between individual positive trials and pooled evidence [46]. reported significant improvements in several inflammatory and oxidative biomarkers with δ -tocotrienol [50]. likewise reported improvements in cardiometabolic factors, hs-CRP, IL-6, TNF- α , MDA and antioxidant capacity with a combination of δ -tocotrienol and resveratrol in metabolic syndrome. A companion randomised analysis of the same combination reported upregulation of miR-130b-5p and miR-221-5p and downregulation of miR-122-5p, providing an epigenetic signal but still not isolating the independent contribution of δ -tocotrienol [51]. Because both studies used two biologically active compounds, neither can establish the independent effect of tocotrienol.

Meta-analytic evidence is more cautious [22]. found a reduction in CRP but identified that the result was substantially driven by a single δ -tocotrienol study; pooled IL-6, TNF- α and MDA changes were not significant [21]. similarly found no consistent effect across numerous inflammatory, glycaemic, hepatic and anthropometric markers.

This discrepancy may have several explanations. First, purified δ -tocotrienol and mixed TRF should not necessarily be expected to produce identical pharmacodynamics. Second, systemic exposure varies substantially across formulations. Third, baseline inflammation may determine detectability of benefit; reducing CRP in a participant with marked meta-inflammation is biologically different from attempting to reduce an already-low value. Fourth, background treatment can decrease the residual biomarker range available for improvement. Finally, small single-center studies are inherently more susceptible to unstable estimates than pooled evidence.

Figure 2 summarizes the resulting overlap problem. Oxidative stress, inflammatory signalling, insulin resistance, and renal injury are not pathways uniquely targeted by tocotrienols. SGLT2 inhibitors and GLP-1 RAs influence many of the same biological systems, while finerenone modifies inflammatory and fibrotic kidney signalling.

 Residual pathway	 Modern therapy	 Palm tocotrienols	 Interpretation
 Oxidative stress	SGLT2i / GLP-1 RA	Antioxidant / redox effects	Overlap; incremental effect uncertain
 NLRP3 / NF-κB	SGLT2i / GLP-1 RA	Anti-inflammatory signalling	Potential complementarity or redundancy
 Insulin resistance	GLP-1 / weight therapy	HOMA-IR signals in small trials	Likely modest adjunctive domain
 Kidney injury	SGLT2i / GLP-1 / finerenone	Small eGFR signal; UACR inconsistent	Requires modern add-on trials
 Microvascular dysfunction	Risk-factor control	Nerve-conduction signal	Hypothesis-generating
 Hard CV/ kidney outcomes	Large outcome trials	No definitive outcome trials	Major evidence gap
 <i>A shared molecular target does not by itself establish additive clinical benefit. Additivity must be demonstrated against the contemporary standard-of-care background.</i>			

Figure 2: Mechanistic Overlap, Complementarity and Possible Redundancy

Figure 2 illustrates that mechanistic overlap can produce either complementarity or redundancy. If the interventions act at different points within a causal pathway and residual abnormality remains, additive effects are plausible. If modern pharmacotherapy already substantially normalizes the relevant pathway, another intervention may produce little incremental benefit despite showing activity when tested alone. Consequently, mechanistic diagrams should generate hypotheses for combination trials rather than serve as evidence that combinations will work.

Theme 6: Kidney and Microvascular Findings are Intriguing but Preliminary

A phase IIb trial in diabetic kidney disease provides one of the most clinically interesting tocotrienol signals [52]. randomised patients with DKD to tocotrienol-rich vitamin E or placebo. Tocotrienol supplementation reduced serum creatinine and improved eGFR at selected time points, with a persistent signal in the stage-3 CKD subgroup over 12 months. However, urinary albumin-to-creatinine ratio did not improve significantly, and measured TGF-β1 and VEGF-A concentrations did not explain the renal-function changes. The benefits also disappeared after washout.

This pattern should encourage investigation while restraining clinical claims. eGFR improvement without corresponding albuminuria improvement is not intrinsically invalid because renal interventions can affect different components of kidney physiology. Nevertheless, the small sample, lack of a hard kidney endpoint and absence of a clear biomarker correlate make the result hypothesis-generating rather than practice-changing. Most importantly, the trial predates widespread contemporary layering of SGLT2 inhibition, GLP-1 therapy and finerenone. Whether a similar signal would remain detectable in 2026 standard care is unknown.

Neuropathy findings show comparable complexity [53]. reported improved median and sural sensory nerve conduction velocity after 12 months of tocotrienol-rich vitamin-E supplementation in T2DM. Serum TGF-β1 and VEGF-A did not change, and the nerve-conduction benefits diminished after washout. The trial suggests a biological microvascular or neuroprotective signal but does not establish durable functional benefit, symptom improvement or prevention of clinically important neuropathic

complications. These studies collectively demonstrate why organ-specific outcomes deserve greater attention than HbA1c alone. Tocotrienols could theoretically affect tissue injury even if their glucose-lowering effect is small. Yet organ-level signals must ultimately be tested against treatments already known to prevent kidney failure, heart failure and cardiovascular events.

Theme 7: Product Identity and Bioavailability are Major Sources of Heterogeneity

The clinical literature often uses “tocotrienol” as though it represented a uniform exposure. It does not. Trials include mixed palm TRF, purified δ-tocotrienol, tocotrienol-containing food preparations and combination products. The relative amounts of α-, γ- and δ-tocotrienols differ, as do tocopherol content, excipients and delivery technologies [24]. demonstrated that pharmacokinetic properties differ between annatto-based and palm-derived preparations and among tocotrienol isomers [25] further reviewed self-emulsifying delivery technologies designed to address poor aqueous solubility and variable oral bioavailability. Accordingly, dose stated in milligrams is an incomplete measure of pharmacological exposure.

A 2025 randomised trial of tocotrienol-enriched oat supplementation in metabolic syndrome illustrates the additional complexity of food matrices [54]. observed improvements in several metabolic variables, but the intervention combined tocotrienol enrichment with an oat-based matrix that has its own metabolic properties. Such studies are useful for food-based intervention science but cannot define the independent pharmacological effect of palm TRF.

Future studies should therefore report verified composition, isomer concentrations, tocopherol content, formulation characteristics, adherence and, ideally, circulating tocotrienol concentrations. Without these data, apparently inconsistent trials may reflect inconsistent exposure rather than inconsistent biology.

Theme 8: There is no Established Incremental Efficacy on Modern Standard Therapy

The decisive evidence gap is not whether tocotrienols can change biomarkers. It is whether they improve outcomes in addition to

contemporary therapy. None of the principal tocotrienol clinical trials establishes additive benefit in a population systematically treated with an SGLT2 inhibitor, GLP-1 RA, optimised RAS blockade, appropriate statin therapy and finerenone where indicated. This gap has become more consequential because the current therapeutic classes themselves modify inflammatory and oxidative biology. Reviews by [34–42], collectively illustrate how SGLT2 and GLP-1 therapies influence pathways previously invoked as distinctive rationales for antioxidant nutraceuticals.

The newly published broad review of tocotrienol-rich fraction in diabetes and cardiovascular disease reinforces the biological rationale but also demonstrates why a more contemporary question is needed [55]. The field should now progress from documenting pleiotropy toward experimentally demonstrating incremental value under modern treatment conditions.

Figure 3 depicts this translational gradient. Tocotrienol evidence is most abundant at the mechanistic level, reasonably suggestive at the biomarker level, limited but intriguing for selected organ-specific intermediate endpoints, and currently absent for definitive cardiovascular, kidney-failure or mortality outcomes.




Figure 3: Tocotrienol Evidence Gradient in Contemporary Metabolic Medicine

Figure 3 explains that the strength of the claim should decrease as the translational distance from the evidence increases. Mechanistic antioxidant activity can support biological plausibility but cannot establish prevention of kidney failure. Small improvements in HbA1c or nerve-conduction velocity can justify phase-II development but cannot be equated with reduced cardiovascular events. The largest research gap therefore occurs at the end of the clinical-outcome pathway, exactly where contemporary SGLT2, GLP-1 and finerenone evidence is strongest.

Discussion and Critical Analysis

Does Meaningful Residual Biological Space Remain for Tocotrienols?

The answer to the first research question is qualified but affirmative. Modern T2DM pharmacotherapy dramatically improves outcomes but does not restore normal metabolism. Many individuals continue to experience obesity, insulin resistance, albuminuria, endothelial dysfunction, inflammatory activation and progressive organ disease despite appropriate treatment. The concept of residual inflammatory or oxidative risk therefore remains biologically reasonable [38,43].

However, identifying a residual abnormality is only the beginning of a therapeutic argument. To justify another intervention, the residual pathway must be modifiable, the intervention must reach the relevant tissue at an adequate concentration, and altering the pathway must improve an outcome that matters. Traditional antioxidant trials in cardiovascular and metabolic medicine

illustrate the danger of assuming that oxidative stress biomarkers automatically identify an antioxidant-responsive clinical condition [31].

For tocotrienols, the strongest rationale may consequently be targeted rather than universal. A participant with high oxidative burden, early diabetic kidney dysfunction, preserved renal reserve or short-duration T2DM might differ from a participant with advanced complications and low inflammatory activity. Such heterogeneity could help explain why subgroup and individual-trial findings appear stronger than overall meta-analytic estimates.

Complementarity Versus Redundancy is the Central Pharmacological Question

The second research question concerns interaction with contemporary therapy. Tocotrienols and SGLT2 inhibitors both influence oxidative and inflammatory pathways, but they do so from different primary pharmacological starting points. SGLT2 inhibition begins with renal glucose/sodium transport and changes intraglomerular haemodynamics, tubular workload, energetics and systemic metabolism. Tocotrienols interact with lipid environments and multiple signalling systems. These differences create potential complementarity even when downstream pathways overlap [19,33].

GLP-1 RAs create a more complex comparison because they reduce upstream drivers such as body weight, food intake, postprandial glycaemia and systemic inflammation. Ussher and Drucker [40].

describe cardiovascular mechanisms extending beyond glucose lowering, while [41]. demonstrated sizeable CRP reductions during semaglutide therapy. If tocotrienol benefits are most apparent in states of metabolic inflammation, substantial GLP-1-induced weight loss could either enhance benefit by improving overall metabolic responsiveness or reduce the marginal tocotrienol effect by removing the inflammatory substrate it would otherwise modify. A recent comparison of GLP-1 RAs and SGLT2 inhibitors similarly concluded that the two classes converge on systemic inflammation through partially divergent proximal pathways, strengthening the case for testing rather than assuming additivity with other anti-inflammatory interventions [56].

Finerenone creates a similar issue in DKD. Its clinical effects are supported by hard outcome trials, whereas renal tocotrienol evidence presently rests on a small phase-II study. A scientifically appropriate future trial should therefore evaluate tocotrienols on top of RAS blockade, SGLT2 inhibition and indicated finerenone, rather than compare tocotrienols with those treatments.

The consequence is important: the modern therapeutic environment may make it harder for tocotrienols to show benefit, but this is the standard they must meet. A smaller incremental effect on a background of effective treatment can still be valuable if it is safe, reproducible, affordable and clinically important, but demonstrating it requires substantially larger and better-designed studies.

Why are the Clinical Results Inconsistent?

Several sources of heterogeneity emerge from the contemporary evidence. These sources operate at the levels of product composition, systemic exposure, baseline phenotype, background pharmacotherapy, endpoint selection and statistical power, and they should be considered together rather than as isolated explanations.

First, product heterogeneity is substantial. Mixed palm TRF is not pharmacologically identical to purified δ -tocotrienol, annatto-derived preparations, modified tocotrienol compounds or tocotrienol-fortified foods [24–25]. demonstrate why absorption and formulation cannot be treated as secondary details.

Second, dose alone is a poor measure of exposure. A nominal 300–400 mg daily dose can yield different systemic concentrations depending on formulation, meal timing, matrix and isomer composition. Studies that do not measure circulating tocotrienols cannot determine whether a nonresponse represents biological inefficacy or inadequate exposure.

Third, baseline phenotype differs. The stronger effect observed in shorter-duration T2DM in the meta-analysis by [20]. Suggests that disease duration may matter. Early disease may retain metabolic reversibility, whereas advanced disease reflects established structural injury.

Fourth, background pharmacotherapy is heterogeneous. Older and small nutraceutical trials frequently enrolled participants receiving conventional oral glucose-lowering agents but not necessarily SGLT2 inhibitors or GLP-1 RAs. Consequently, historical effect sizes cannot be assumed to apply to contemporary care.

Fifth, endpoint selection varies. HbA1c reflects average glycaemic exposure but is poorly suited to detecting a purely anti-inflammatory or renal-microvascular effect. hs-CRP is convenient but nonspecific. MDA assays vary analytically. Serum creatinine and eGFR can be influenced by haemodynamics and biological

variability. Nerve-conduction velocity may improve without corresponding symptom relief. A multidimensional intervention requires endpoints mapped explicitly to its proposed mechanism. Sixth, sample sizes remain small. The DKD phase-II trial included 59 participants, the neuropathy trial 88, and several metabolic studies approximately 70–110 participants. Such studies are appropriate for signal detection but inherently unsuitable for defining modest cardiorenal effects or rare adverse events [46–53].

The Case for Moving Beyond HbA1c

HbA1c should remain an important endpoint because sustained hyperglycaemia drives complications. Nevertheless, modern diabetes care demonstrates that clinically important effects can be partly independent of HbA1c. SGLT2 inhibitors produce kidney and heart-failure protection disproportionate to their modest glucose-lowering effect in CKD, and GLP-1 RAs provide cardiovascular benefits through a combination of metabolic and nonglycaemic mechanisms [15–16]. Tocotrienol trials should therefore use multidomain endpoint panels. Continuous glucose monitoring can characterize time in range, postprandial excursions and glycaemic variability. Fasting insulin or HOMA-IR may provide pragmatic metabolic indicators, supplemented by clamp methodology in mechanistic substudies. Oxidative/inflammatory profiling should combine hs-CRP with selected cytokines, redox markers and lipid-oxidation products rather than rely on a single assay.

Kidney trials should measure UACR repeatedly, standardised eGFR slope, cystatin-C where feasible and emerging tubular or inflammatory biomarkers. Neuropathy studies should combine electrophysiology with validated pain, sensory and functional outcomes. Vascular studies could use endothelial-function measures alongside circulating markers. Such endpoint triangulation would determine whether a biochemical signal actually corresponds to tissue-level benefit.

A Precision-Adjunct Hypothesis is More Defensible than Universal Supplementation

The available evidence does not support routine tocotrienol supplementation for every person with T2DM. It does, however, support a testable hypothesis that selected phenotypes may derive greater benefit.

One candidate phenotype is shorter-duration T2DM with persistent insulin resistance, given the subgroup pattern in [20]. and positive metabolic effects observed by [46]. A second is prediabetes or early dysglycaemia, where residual β -cell capacity and metabolic flexibility may make modification more feasible [47].

A third candidate is T2DM with metabolic liver disease or visceral adipose dysfunction. δ -Tocotrienol trials in nonalcoholic fatty liver disease, now generally framed within the broader concept of metabolic dysfunction-associated steatotic liver disease (MASLD), demonstrate changes in insulin resistance, hepatic-steatosis indices, inflammation and adipokines [48–19].

These data do not prove efficacy in T2DM with MASLD but support phenotype-directed testing.

A fourth is early diabetic CKD with persistent inflammatory or oxidative activity despite optimised therapy [52]. kidney signal warrants replication, but any new trial must account for modern SGLT2 and finerenone use.

A fifth possibility is low vitamin-E or tocotrienol exposure status, although suitable thresholds and causal implications require

clarification. Baseline nutritional status may alter the response to supplementation and should therefore be measured rather than assumed.

Precision selection could increase statistical power by enriching populations in whom the hypothesized pathway is active. Nevertheless, biomarker enrichment must be prospectively defined to avoid retrospective identification of apparently responsive subgroups.

Next-Generation Trial Design

The critical next step is not another small trial of tocotrienol versus placebo on loosely defined “usual care.” The relevant design is a contemporary add-on trial.

Participants should have T2DM and a prespecified residual-risk phenotype despite stable guideline-directed therapy. Background medications should be documented rigorously, including SGLT2 inhibitor use, GLP-1 or dual incretin therapy, RAS blockade, statins, finerenone and other glucose-lowering drugs. Randomization should occur only after a stabilisation period sufficient to prevent background medication changes from being confused with tocotrienol effects.

The intervention should use a chemically characterised palm-derived TRF or clearly defined palm tocotrienol isomer preparation. Batch composition, tocotrienol/tocopherol ratio, pharmaceutical formulation and stability should be reported. Adherence should be supplemented by plasma tocotrienol measurements in a pharmacokinetic subset.

Stratification should include kidney status, diabetes duration and major metabolic phenotype. An inflammatory-redox enrichment strategy could be explored if validated biomarkers are available. Participants should not be selected simply because a biomarker is statistically elevated; the biomarker should have biological relevance to the proposed tocotrienol mechanism.

Intermediate endpoints could include HbA1c, CGM metrics, insulin resistance, hs-CRP, IL-6, TNF- α , selected redox markers, UACR and standardised eGFR slope. Organ-specific substudies could examine nerve conduction, endothelial physiology or hepatic fat. Safety endpoints should include adverse events, liver and kidney biochemistry, interactions with anticoagulant or antiplatelet therapy where relevant and treatment discontinuation.

Ultimately, sufficiently large and long studies must determine whether biological effects translate into durable kidney, cardiovascular or microvascular benefit. The clinical evidence threshold for a nutritional adjunct does not need to equal that of a new pharmaceutical for every use case, but claims of cardiorenal protection require cardiorenal evidence.

Figure 4 presents a proposed next-generation architecture in which tocotrienol is tested after stabilisation of contemporary therapy, participants are phenotyped before randomisation, formulation and exposure are verified, and mechanistic endpoints are connected explicitly to organ-level outcomes. It also links these design choices to both intermediate and clinically meaningful endpoints, making the evidentiary pathway from mechanism to patient benefit explicit.




Figure 4: Proposed Next-Generation Trial Architecture for Palm Tocotrienols

Figure 4 shows that this trial structure addresses several weaknesses of the existing literature simultaneously. Standardized background therapy tests incremental efficacy; phenotyping reduces biological heterogeneity; pharmacokinetic confirmation distinguishes nonresponse from inadequate exposure; and a hierarchy of intermediate and clinically meaningful endpoints prevents favourable biomarker changes from being overinterpreted. The approach would also allow prespecified evaluation of whether renal, inflammatory, metabolic or nutritional phenotypes identify responders.

Safety, Clinical Positioning and Translational Discipline

The clinical trials considered in this review generally describe tocotrienol supplementation as well-tolerated, but small samples are insufficient to establish rare-event safety. Product quality is equally important. Commercial “vitamin E” supplements may not reproduce the composition used in clinical studies, and varying amounts of tocopherol or different tocotrienol isomers may influence both pharmacokinetics and biological effects.

Tocotrienols should therefore be positioned as potential adjuncts rather than replacements for therapies with established outcome benefits. Patients with T2DM and CKD should not substitute a tocotrienol supplement for an indicated SGLT2 inhibitor, GLP-1 RA, RAS blocker or finerenone based on antioxidant reasoning. The evidence supporting those pharmacological therapies includes large randomised clinical outcome trials, whereas tocotrienol evidence remains predominantly mechanistic and phase-II in nature.

This distinction is especially important for scientific communication. Descriptions such as “antidiabetic,” “renoprotective” or “cardioprotective” should specify the level of evidence. Tocotrienols can appropriately be described as demonstrating antidiabetic or organ-protective signals in selected studies; definitive claims of prevention of cardiovascular events, kidney failure or diabetes complications would exceed the current clinical evidence.

Relationship to the Emerging 2026 Literature

Ali et al. recently synthesized molecular and clinical literature concerning tocotrienol-rich fraction in diabetes and cardiovascular disease. The publication confirms continued interest in TRF and provides a broad overview of its pleiotropic pharmacology. Its appearance also makes conceptual differentiation essential for subsequent reviews.

The present review advances a distinct question. Rather than asking whether TRF has mechanisms relevant to diabetes and cardiovascular disease, it asks whether those mechanisms retain incremental therapeutic meaning after the standard-of-care environment has changed. The comparison with SGLT2 inhibitors, GLP-1 RAs and finerenone therefore becomes central rather than peripheral.

This approach shifts the field from a molecule-centered model to a treatment-system model. The biological activity of a candidate adjunct is evaluated in the context of what patients are already receiving, which pathways those therapies already modify, what residual risks remain, and what evidence would be required to justify adding another intervention.

Conclusion

Palm-derived tocotrienols remain scientifically interesting in T2DM because they interact with biological systems that continue to contribute to metabolic and organ injury: oxidative stress, inflammatory signalling, insulin resistance, endothelial dysfunction and related microvascular pathways. Contemporary human studies provide evidence of modest improvements in glycaemic control and selected metabolic biomarkers, while individual trials suggest possible effects on diabetic kidney function, nerve conduction and metabolic liver disease. These signals justify continued research.

The clinical interpretation, however, must change with the therapeutic era. SGLT2 inhibitors, GLP-1–based therapies, optimised RAS blockade and finerenone now provide cardiovascular and kidney benefits supported by large randomised outcome trials. These treatments also modify several inflammatory, oxidative, metabolic and vascular pathways that have traditionally been invoked to justify tocotrienol supplementation. Consequently, demonstration that tocotrienols possess antioxidant or anti-inflammatory activity is no longer sufficient to establish a therapeutic niche.

The principal unanswered question is incremental efficacy. Current evidence does not establish that adding palm-derived tocotrienols to contemporary guideline-directed therapy reduces cardiovascular events, kidney failure, mortality or other hard diabetic outcomes. Even the most encouraging kidney and neurological trials remain small, use intermediate endpoints and largely predate current multidrug cardiorenal management.

Future investigations should therefore abandon the assumption of a universal tocotrienol class effect. Trials should specify the palm-derived formulation and isomer composition, verify exposure, stratify participants by disease duration and metabolic or renal phenotype, document background SGLT2/GLP-1/finerenone treatment and link mechanistic biomarkers to clinically meaningful endpoints. Biomarker-enriched designs may be particularly useful for identifying oxidative-inflammatory responder phenotypes.

The most defensible present position is thus neither rejection nor routine clinical adoption. Palm tocotrienols should be regarded as a promising precision-adjunct hypothesis whose biological plausibility is ahead of its outcome evidence. Demonstrating whether that hypothesis has clinical value will require studies designed for the realities of modern T2DM treatment rather than the therapeutic environment in which nutraceutical antioxidant research originally developed.

References

1. GBD 2021 Diabetes Collaborators (2023) Global, regional, and national burden of diabetes from 1990 to 2021 with projections of prevalence to 2050 A systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 402: 203-234.
2. American Diabetes Association Professional Practice Committee for Diabetes (2026) Obesity and weight management for the prevention and treatment of diabetes Standards of Care in Diabetes 2026. *Diabetes Care* 49: 166-182.
3. American Diabetes Association Professional Practice Committee for Diabetes (2026) Pharmacologic approaches to glycemic treatment Standards of Care in Diabetes-2026. *Diabetes Care* 49: 183-215.
4. American Diabetes Association Professional Practice Committee for Diabetes (2026) Cardiovascular disease and risk management Standards of Care in Diabetes-2026. *Diabetes Care* 49: 216-245.
5. American Diabetes Association Professional Practice Committee for Diabetes (2026) Chronic kidney disease and risk management Standards of Care in Diabetes-2026. *Diabetes Care* 49: 246-260.
6. Heerspink, HJL, Stefansson BV, Correa-Rotter R, Chertow MG, Tom Greene, et al. (2020) Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*. 383:1436-1446.
7. EMPA KIDNEY Collaborative Group (2023). Empagliflozin in patients with chronic kidney disease. *N Engl J Med*. 388: 117–127.
8. EMPA KIDNEY Collaborative Group (2025) Long term effects of empagliflozin in patients with chronic kidney disease. *N Engl J Med* 392: 777-787.
9. Bakris GL, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M. Ruilope, et al. (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N. Engl J Med* 383: 2219-2229.
10. Pitt B, Bertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, George L Bakris, et al. (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N Engl J Med* 385: 2252-2263.

11. Rajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, Stefan D Anker, Peter Rossing, et al. (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease The FIDELITY pooled analysis. *Eur Heart J* 43: 474-484.
12. Lincoff AM, Michael Lincoff A, Kirstine Brown Frandsen, Helen Colhoun M, John Deanfield, Scott Emerson S, et al. (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med* 389: 2221-2232.
13. Vlado Perkovic, Katherine Tuttle R, Peter Rossing DM, Kenneth Mahaffey W, et al. (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med* 391: 109-121.
14. Stephen Nicholls J, Imre Pavo, Deepak Bhatt L, John Buse B, Stefano Del Prato, et al. (2025) Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. *N Engl J Med* 393: 2409-2420.
15. Darren McGuire K, Weichung Shih J, Francesco Cosentino, et al. (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes A meta-analysis. *JAMA Cardiol* 6: 148-158.
16. Sunil Badve V, Anika Bilal, Matthew Lee MY, Naveed Sattar, Hertzel Gerstein C, et al. (2025) Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes A meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol* 13: 15-28.
17. Bae JH (2025) SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease evolving evidence and clinical application. *Diabetes Metab J* 49: 386-402.
18. Szewczyk K, Chojnacka A, Górnicka M (2021) Tocopherols and tocotrienols Bioactive dietary compounds what is certain what is doubt. *J Mol Sci* 22: 6222.
19. Ranasinghe R, Mathai M Zulli A (2022) Revisiting the therapeutic potential of tocotrienol. *BioFactors* 48: 813-856.
20. Phang SCW, Ahmad B, Abdul Kadir K, Palanisamy UDM (2023) Effects of tocotrienol rich fraction supplementation in patients with type 2 diabetes A systematic review and meta-analysis of randomized controlled trials. *Adv Nutr* 14: 1159-1169.
21. Li F, Xu B, Soltanich S, Zanghelini F, Abu Zaid A, et al. (2022) The effects of tocotrienols intake on obesity blood pressure inflammation liver and glucose biomarkers A meta-analysis of randomized controlled trials. *Food Sci Nutr* 62: 7154-7167.
22. Ban Hock Khor, Hui Ci Tiong, Shing Cheng Tan, Sok Kuan Wong, Kok Yong Chin, et al. (2021) Effects of tocotrienols supplementation on markers of inflammation and oxidative stress A systematic review and meta-analysis of randomized controlled trials. *PLoS ONE* 16: e0255205.
23. Looi AD, Palanisamy UD, Moorthy M, Radhakrishnan AK (2025) Health benefits of palm tocotrienol rich fraction a systematic review of randomized controlled trials. *Nutr Rev* 83: 307-328.
24. Sharif M, Khan DA, Farhat K, Noor M, Khan MA, et al. (2023) Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers A systematic review. *J Pak Med Assoc* 73: 603-610.
25. Mohamad NV (2023) Strategies to enhance the solubility and bioavailability of tocotrienols using self-emulsifying drug delivery system. *Pharmaceutics* 16: 1403.
26. Lima JEBF, Moreira NCS, Sakamoto Hojo ET (2022) Mechanisms underlying the pathophysiology of type 2 diabetes from risk factors to oxidative stress metabolic dysfunction and hyperglycemia. *Genet Toxicol Environ Mutagen* 874-875.
27. Jasvinder Singh Bhatti, Abhishek Sehrawat, Jayapriya Mishra, Inderpal Singh Sidhu, Umashanker Navik, et al. (2022) Oxidative stress in the pathophysiology of type 2 diabetes and related complications Current therapeutic strategies and futures perspectives. *Free Radic Biol Med* 184: 114-134.
28. Chen X, Zhang D, Li Y, Wang W, Bei W, et al. (2021) NLRP3 inflammasome and IL-1 β pathway in type 2 diabetes and atherosclerosis Friend or foe. *Pharmacol Res* 173: 105885.
29. Olona A, Leishman S, Anand PK (2022) The NLRP3 inflammasome Regulation by metabolic signals. *Trends Immunol* 43: 978-989.
30. Lee J, Yun JS, Ko SH (2022) Advanced glycation end products and their effect on vascular complications in type 2 diabetes mellitus. *Nutrients* 14: 3086.
31. Xin Li, Junyong Zou, Aiping Lin, Jingshu Chi, Hong Hao, et al. (2024) Oxidative stress endothelial dysfunction and N-acetylcysteine in type 2 diabetes mellitus. *Antioxid Redox Signal* 40: 968-989.
32. Martinez Leon V, Hilburg R, Susztak K (2026) Mechanisms of diabetic kidney disease and established and emerging treatments. *Nat Rev Endocrinol* 22: 21-35.
33. Fonseca Correa JI, Correa Rotter R (2021) Sodium-glucose cotransporter 2 inhibitors mechanisms of action A review. *Front Med* 8: 777861.
34. van Ruiten CC, Hesp AC, van Raalte DH (2022) Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis Update on recent mechanistic insights related to kidney physiology. *Eur J Intern Med* 100: 13-20.
35. Klen J, Dolžan V (2023) SGLT2 inhibitors in the treatment of diabetic kidney disease More than just glucose regulation. *Pharmaceutics* 15: 1995.
36. Bray JJH, Foster Davies H, Stephens JW (2020) A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors on biomarkers of inflammation and oxidative stress. *Diabetes Res. Clin Pract* 168: 108368.
37. Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T, et al. (2021) Inflammation and oxidative stress in diabetic kidney disease the targets for SGLT2 inhibitors and GLP-1 receptor agonists. *Int J Mol Sci* 22: 10822.
38. Oda Y, Nishi H, Nangaku M (2023) Role of inflammation in progression of chronic kidney disease in type 2 diabetes mellitus: Clinical implications. *Semin Nephrol* 43: 151431.
39. Mashayekhi M, Safa BI, Gonzalez MSC, Kim SF, Echouffo-Tcheugui JB, et al. (2024) Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors. *Trends Endocrinol* 35: 425-438.
40. Ussher JR, Drucker DJ (2023) Glucagon-like peptide 1 receptor agonists Cardiovascular benefits and mechanisms of action. *Nat Rev Cardio* 20: 463-474.
41. Subodh Verma, Meena Bhatta, Melanie Davies, John Deanfield E, Timothy Garvey W, et al. (2023) Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity Exploratory analyses of three randomised double-blind placebo-controlled phase 3 trials. *EClinical Medicine* 55: 101737.
42. Alharbi SH, (2024) Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. *Ther Adv Endocrinol* 15: 20420188231222367.
43. Alessia Aiello D, Alice Bonanni, Ramona Vinci, Daniela Pedicino, Anna Severino, et al. (2023) Meta-inflammation and new anti-diabetic drugs: A new chance to knock down residual cardiovascular risk. *J Mol Sci* 24: 8643.
44. Parijat De, May Khine T, Andrew Frankel, Gabrielle Goldet, Debasish Banerjee, et al. (2025) Finerenone in the management of diabetes kidney disease. *BMC Nephrol* 26: 63.

45. Parijat De, May Khine T, Andrew Frankel, Gabrielle Goldet, Debasish Banerjee, et al. (2021) Dehydro-tocotrienol- β counteracts oxidative-stress-induced diabetes complications in db/db mice. *Antioxidants* 10: 1070.
46. Mahjabeen W, Khan DA, Mirza SA, Pervez MA (2021) Effects of delta-tocotrienol supplementation on glycemic control oxidative stress inflammatory biomarkers and miRNA expression in type 2 diabetes mellitus A randomized control trial. *Phytother Res* 35: 3968-3976.
47. Suleman F, Khan DA, Pervez MA, Aamir M (2022) Effects of delta-tocotrienol supplementation on glycaemic control in individuals with prediabetes A randomized controlled study. *J Pak Med Assoc* 72: 4-7.
48. Pervez MA, Khan DA, Slehria AUR, Ijaz A (2020) Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease A randomized, placebo-controlled trial. *Complement. Ther Med* 52: 102494.
49. Pervez MA, Khan DA, Mirza SA, Slehria AUR, Nisar U, et al. (2022) Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease A randomized double-blind active-controlled trial. *Complement Ther Med* 70: 102866.
50. Fatima S, Khan DA, Aamir M, Pervez MA, Fatima F (2023) δ -Tocotrienol in combination with resveratrol improves the cardiometabolic risk factors and biomarkers in patients with metabolic syndrome A randomized controlled trial. *Syndr Relat Disord* 21: 25-34.
51. Safia Fatima, Dilshad Ahmed Khan, Fozia Fatima, Muhammad Aamir, Aamir Ijaz, et al. (2023) Role of δ -tocotrienol and resveratrol supplementation in the regulation of micro RNAs in patients with metabolic syndrome a randomized controlled trial. *Complement Ther Med* 74-102950.
52. Yan Yi Koay, Gerald Chen Jie Tan, Sonia Chew Wen Phang, J-Ian Ho, Pei Fen Chuar, Pei Fen Chuar, et al. (2021) A Phase IIb randomized controlled trial investigating the effects of tocotrienol-rich vitamin E on diabetic kidney disease. *Nutrients* 13-258.
53. Pei Fen Chuar, Yeek Tat Ng, Sonia Chew Wen Phang, Yan Yi Koay, J Ian Ho, et al. (2021) Tocotrienol-rich vitamin E (Tocovid) improved nerve conduction velocity in type 2 diabetes mellitus patients in a Phase II double-blind randomized controlled clinical trial. *Nutrients* 13: 3770.
54. Norazman CW, Sopian MM, Lee LK (2025) Effects of tocotrienol-enriched oat supplementation on metabolic profile, nutritional status and health-related quality of life among patients with metabolic syndrome. *Food Funct* 16: 1847-1863.
55. Ali M, Sheikh Abdul Kadir SH, Ibrahim E, Albaraikan A (2026) Tocotrienol-rich fraction of vitamin E in diabetes and cardiovascular disease from molecular mechanisms to clinical application. *J Cardiol Cardiovasc Risk Prev* 30: 200686.
56. Samuel AH, Singh Kshatri AH, Nanda Babu R, Shirishkumar P, Viswanathan SH, et al. (2026) GLP-1 RAs vs SGLT2is divergent pathways of cardiovascular inflammation control in obesity-associated diabetes. *Ann Endocrinol* 87: 102494.